메뉴 건너뛰기




Volumn 24, Issue 4, 2015, Pages 499-505

Escherichia coli Nissle 1917 in ulcerative colitis treatment: Systematic review and meta-analysis

Author keywords

Escherichia coli Nissle; Inflammatory bowel disease; Microbiota; Probiotics; Ulcerative colitis

Indexed keywords

MESALAZINE; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT;

EID: 84949199022     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.244.ecn     Document Type: Review
Times cited : (81)

References (36)
  • 1
    • 47949120118 scopus 로고    scopus 로고
    • Clinical use of E. coli Nissle 1917 in inflammatory bowel disease
    • Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1012-1018. doi: 10.1002/ibd.20377
    • (2008) Inflamm Bowel Dis , vol.14 , pp. 1012-1018
    • Schultz, M.1
  • 2
    • 3843116530 scopus 로고    scopus 로고
    • Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917
    • Grozdanov L, Raasch C, Schultz J, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 2004; 186: 5432-5441. doi: 10.1128/JB.186.16.5432-5441.2004
    • (2004) J Bacteriol , vol.186 , pp. 5432-5441
    • Grozdanov, L.1    Raasch, C.2    Schultz, J.3
  • 3
    • 34248399194 scopus 로고    scopus 로고
    • Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin
    • Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007; 75: 2399-2407. doi: 10.1128/IAI.01563-06
    • (2007) Infect Immun , vol.75 , pp. 2399-2407
    • Schlee, M.1    Wehkamp, J.2    Altenhoefer, A.3    Oelschlaeger, T.A.4    Stange, E.F.5    Fellermann, K.6
  • 4
    • 0029129487 scopus 로고
    • Stimulation of intestinal immune cells by E. coli in gnotobiotic piglets
    • Mestecky J, ed. New York: Plenum Press
    • Mandel L, Trebichavsky I, Splichal I, et al. Stimulation of intestinal immune cells by E. coli in gnotobiotic piglets. In: Mestecky J, ed. Advances in Mucosal Immunology. New York: Plenum Press; 1995: 463-464.
    • (1995) Advances in Mucosal Immunology. , pp. 463-464
    • Mandel, L.1    Trebichavsky, I.2    Splichal, I.3
  • 5
    • 4644228771 scopus 로고    scopus 로고
    • Establishment of E. coli Nissle 1917 and its interaction with Candida albicans in gnotobiotic rats
    • Lorenz A, Schulze J. Establishment of E. coli Nissle 1917 and its interaction with Candida albicans in gnotobiotic rats. Microecol Ther 1996; 24: 45-51.
    • (1996) Microecol Ther , vol.24 , pp. 45-51
    • Lorenz, A.1    Schulze, J.2
  • 6
    • 1642374075 scopus 로고    scopus 로고
    • The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cels by different enteroinvasive bacterial pathogens
    • Altenhoefer A, Oswald S, Sonnenborn U, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cels by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 2004; 40: 223-229. doi: 10.1016/S0928- 8244(03)00368-7
    • (2004) FEMS Immunol Med Microbiol , vol.40 , pp. 223-229
    • Altenhoefer, A.1    Oswald, S.2    Sonnenborn, U.3
  • 7
    • 33846894974 scopus 로고    scopus 로고
    • Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair
    • Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9: 804-816. doi: 10.1111/j.1462-5822.2006.00836.x
    • (2007) Cell Microbiol , vol.9 , pp. 804-816
    • Zyrek, A.A.1    Cichon, C.2    Helms, S.3    Enders, C.4    Sonnenborn, U.5    Schmidt, M.A.6
  • 8
    • 33750622338 scopus 로고    scopus 로고
    • Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917
    • Valdebenito M, Crumbliss AL, Winkelmann G, Hantke K. Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. Int J Med Microbiol 2006; 296: 513-520. doi: 10.1016/j. ijmm.2006.06.003
    • (2006) Int J Med Microbiol , vol.296 , pp. 513-520
    • Valdebenito, M.1    Crumbliss, A.L.2    Winkelmann, G.3    Hantke, K.4
  • 9
    • 20144365358 scopus 로고    scopus 로고
    • Escherichia coli Nissle 1917 distinctively modulates T cell cycling and expansion via toll-like receptor 2 signaling
    • Sturm A, Rilling K, Baumgart DC, et al. Escherichia coli Nissle 1917 distinctively modulates T cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005; 73: 1452-1465. doi: 10.1128/ IAI.73.3.1452-1465.2005
    • (2005) Infect Immun , vol.73 , pp. 1452-1465
    • Sturm, A.1    Rilling, K.2    Baumgart, D.C.3
  • 10
    • 33750239826 scopus 로고    scopus 로고
    • Lactobacilli, bifidobacteria and E. coli Nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells
    • Helwig U, Lammers KM, Rizzello F, et al. Lactobacilli, bifidobacteria and E. coli Nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol 2006; 12: 5978-5986. doi: 10.3748/wjg.v12.i37.5978
    • (2006) World J Gastroenterol , vol.12 , pp. 5978-5986
    • Helwig, U.1    Lammers, K.M.2    Rizzello, F.3
  • 11
    • 33748662190 scopus 로고    scopus 로고
    • Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): Results of a prospective study of the records of 3,807 patients
    • Krammer HJ, Kämper H, von Bünau R, et al. Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients. Z Gastroenterol 2006; 44: 651-656. doi: 10.1055/s-2006-926909
    • (2006) Z Gastroenterol , vol.44 , pp. 651-656
    • Krammer, H.J.1    Kämper, H.2    von Bünau, R.3
  • 12
    • 34248136340 scopus 로고    scopus 로고
    • Inflammatory bowel disease: Clinical aspects and established and evolving therapies
    • Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641- 1657. doi: 10.1016/S0140-6736(07)60751-X
    • (2007) Lancet , vol.369 , pp. 1641-1657
    • Baumgart, D.C.1    Sandborn, W.J.2
  • 13
    • 79955551587 scopus 로고    scopus 로고
    • Regulation of homeostasis and inflammation in the intestine
    • MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011; 140: 1768-1775. doi: 10.1053/j.gastro.2011.02.047
    • (2011) Gastroenterology , vol.140 , pp. 1768-1775
    • McDonald, T.T.1    Monteleone, I.2    Fantini, M.C.3    Monteleone, G.4
  • 17
    • 84904765781 scopus 로고    scopus 로고
    • Therapeutic modulation of gut microbiota: Current clinical applications and future perspectives
    • Ianiro G, Bibbò S, Gasbarrini A, Cammarota G. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives. Curr Drug Targets 2014; 15: 762-770. doi: 10.2174/1389450115666140606111402
    • (2014) Curr Drug Targets , vol.15 , pp. 762-770
    • Ianiro, G.1    Bibbò, S.2    Gasbarrini, A.3    Cammarota, G.4
  • 18
    • 84916229815 scopus 로고    scopus 로고
    • Fecal microbiota transplantation in inflammatory bowel disease: Beyond the excitement
    • Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore) 2014; 93: e97. doi: 10.1097/ MD.0000000000000097
    • (2014) Medicine (Baltimore) , vol.93
    • Ianiro, G.1    Bibbò, S.2    Scaldaferri, F.3    Gasbarrini, A.4    Cammarota, G.5
  • 19
    • 84925595618 scopus 로고    scopus 로고
    • The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
    • Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 2015; 149: 191-212. doi: 10.1016/j.pharmthera.2014.12.006
    • (2015) Pharmacol Ther , vol.149 , pp. 191-212
    • Cammarota, G.1    Ianiro, G.2    Cianci, R.3    Bibbò, S.4    Gasbarrini, A.5    Currò, D.6
  • 20
    • 84907578280 scopus 로고    scopus 로고
    • Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: Is there an involvement of microbiota?
    • Montenegro L, Losurdo G, Licinio R, et al. Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota? Curr Drug Saf 2014; 9: 196-204. doi: 10.2174/1574886309666140424143852
    • (2014) Curr Drug Saf , vol.9 , pp. 196-204
    • Montenegro, L.1    Losurdo, G.2    Licinio, R.3
  • 21
    • 68049137869 scopus 로고    scopus 로고
    • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration
    • Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100. doi: 10.1371/journal.pmed.1000100
    • (2009) PLoS Med , vol.6
    • Liberati, A.1    Altman, D.G.2    Tetzlaff, J.3
  • 23
    • 0029914622 scopus 로고    scopus 로고
    • Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
    • Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. doi: 10.1016/0197-2456(95)00134-4
    • (1996) Control Clin Trials , vol.17 , pp. 1-12
    • Jadad, A.R.1    Moore, R.A.2    Carroll, D.3
  • 24
    • 0030611915 scopus 로고    scopus 로고
    • Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
    • Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858. doi: 10.1046/j.1365-2036.1997.00225.x
    • (1997) Aliment Pharmacol Ther , vol.11 , pp. 853-858
    • Kruis, W.1    Schütz, E.2    Fric, P.3    Fixa, B.4    Judmaier, G.5    Stolte, M.6
  • 25
    • 4644239296 scopus 로고    scopus 로고
    • Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
    • Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623. doi: 10.1136/ gut.2003.037747
    • (2004) Gut , vol.53 , pp. 1617-1623
    • Kruis, W.1    Fric, P.2    Pokrotnieks, J.3
  • 26
    • 77950797408 scopus 로고    scopus 로고
    • Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)
    • Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010; 10: 13. doi: 10.1186/1472-6882-10-13
    • (2010) BMC Complement Altern Med , vol.10 , pp. 13
    • Matthes, H.1    Krummenerl, T.2    Giensch, M.3    Wolff, C.4    Schulze, J.5
  • 27
    • 84927799957 scopus 로고    scopus 로고
    • Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial
    • Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard- Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis 2014; 8: 1498-1505. doi: 10.1016/j.crohns.2014.06.001
    • (2014) J Crohns Colitis , vol.8 , pp. 1498-1505
    • Petersen, A.M.1    Mirsepasi, H.2    Halkjær, S.I.3    Mortensen, E.M.4    Nordgaard-Lassen, I.5    Krogfelt, K.A.6
  • 28
    • 0033592203 scopus 로고    scopus 로고
    • Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
    • Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639. doi: 10.1016/S0140-6736(98)06343-0
    • (1999) Lancet , vol.354 , pp. 635-639
    • Rembacken, B.J.1    Snelling, A.M.2    Hawkey, P.M.3    Chalmers, D.M.4    Axon, A.T.5
  • 29
    • 54049093308 scopus 로고    scopus 로고
    • Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: An open-label pilot study
    • Henker J, Müller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 2008; 46: 874-875. doi: 10.1055/s- 2008-1027463
    • (2008) Z Gastroenterol , vol.46 , pp. 874-875
    • Henker, J.1    Müller, S.2    Laass, M.W.3    Schreiner, A.4    Schulze, J.5
  • 30
    • 84930475582 scopus 로고    scopus 로고
    • Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease
    • Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014; 7: 473-487. doi: 10.2147/CEG.S27530
    • (2014) Clin Exp Gastroenterol , vol.7 , pp. 473-487
    • Ghouri, Y.A.1    Richards, D.M.2    Rahimi, E.F.3    Krill, J.T.4    Jelinek, K.A.5    DuPont, A.W.6
  • 31
    • 84869089859 scopus 로고    scopus 로고
    • Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management
    • Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030. doi: 10.1016/j. crohns.2012.09.002
    • (2012) J Crohns Colitis , vol.6 , pp. 991-1030
    • Dignass, A.1    Lindsay, J.O.2    Sturm, A.3
  • 32
    • 0037309595 scopus 로고    scopus 로고
    • Randomized controlled trial of the effect of bifidobacteria fermented milk on ulcerative colitis
    • Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63.
    • (2003) J Am Coll Nutr , vol.22 , pp. 56-63
    • Ishikawa, H.1    Akedo, I.2    Umesaki, Y.3    Tanaka, R.4    Imaoka, A.5    Otani, T.6
  • 33
    • 33646560334 scopus 로고    scopus 로고
    • Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis
    • Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574. doi: 10.1111/j.1365-2036.2006.02927.x
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 1567-1574
    • Zocco, M.A.1    dal Verme, L.Z.2    Cremonini, F.3
  • 34
    • 59749088586 scopus 로고    scopus 로고
    • Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis
    • Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443. doi: 10.1038/ajg.2008.118
    • (2009) Am J Gastroenterol , vol.104 , pp. 437-443
    • Miele, E.1    Pascarella, F.2    Giannetti, E.3    Quaglietta, L.4    Baldassano, R.N.5    Staiano, A.6
  • 35
    • 37249053411 scopus 로고    scopus 로고
    • High-dose probiotics for the treatment of active pouchitis
    • Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50: 2075-2084. doi: 10.1007/s10350-007-9068-4
    • (2007) Dis Colon Rectum , vol.50 , pp. 2075-2084
    • Gionchetti, P.1    Rizzello, F.2    Morselli, C.3
  • 36
    • 26944448942 scopus 로고    scopus 로고
    • Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in clinical practice
    • Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005; 22: 721-728. doi: 10.1111/j.1365-2036.2005.02642.x
    • (2005) Aliment Pharmacol Ther , vol.22 , pp. 721-728
    • Shen, B.1    Brzezinski, A.2    Fazio, V.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.